List of Elestrin drug patents
Elestrin is owned by Mylan Speciality Lp.
Elestrin contains Estradiol.
Elestrin has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Elestrin are:
- US7198801
Elestrin was authorised for market use on 15 December, 2006.
Elestrin is available in gel, metered;transdermal dosage forms.
The generics of Elestrin are possible to be released after 25 June, 2022.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7198801 | MYLAN SPECIALITY LP | Formulations for transdermal or transmucosal application |
Jun, 2022
(11 months ago) | |
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 15 December, 2006
Treatment: NA
Dosage: GEL, METERED;TRANSDERMAL
ELESTRIN family patents
18
United States
10
European Union
4
Australia
4
Austria
4
Japan
3
Canada
3
New Zealand
3
Spain
3
Germany
3
Mexico
2
Korea, Republic of
2
Brazil
2
China
2
South Africa
1
Israel
1
Denmark
1
Portugal
1
Poland
1
Hong Kong
1
Argentina
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic